Logo image of OCS

OCULIS HOLDING AG (OCS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OCS - CH1242303498 - Common Stock

19 USD
+0.09 (+0.48%)
Last: 11/28/2025, 7:52:40 PM
19.26 USD
+0.26 (+1.37%)
After Hours: 11/21/2025, 8:00:02 PM
Fundamental Rating

2

OCS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. OCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OCS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OCS has reported negative net income.
OCS had a negative operating cash flow in the past year.
OCS had negative earnings in each of the past 5 years.
OCS had a negative operating cash flow in each of the past 5 years.
OCS Yearly Net Income VS EBIT VS OCF VS FCFOCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -62.02%, OCS is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
The Return On Equity of OCS (-79.71%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.02%
ROE -79.71%
ROIC N/A
ROA(3y)-84.45%
ROA(5y)-75.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCS Yearly ROA, ROE, ROICOCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCS Yearly Profit, Operating, Gross MarginsOCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

OCS has more shares outstanding than it did 1 year ago.
OCS has a worse debt/assets ratio than last year.
OCS Yearly Shares OutstandingOCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
OCS Yearly Total Debt VS Total AssetsOCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 13.25 indicates that OCS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 13.25, OCS belongs to the best of the industry, outperforming 85.42% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that OCS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, OCS is in line with its industry, outperforming 56.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 13.25
ROIC/WACCN/A
WACCN/A
OCS Yearly LT Debt VS Equity VS FCFOCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.47 indicates that OCS has no problem at all paying its short term obligations.
The Current ratio of OCS (4.47) is better than 63.02% of its industry peers.
A Quick Ratio of 4.47 indicates that OCS has no problem at all paying its short term obligations.
OCS's Quick ratio of 4.47 is fine compared to the rest of the industry. OCS outperforms 64.58% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
OCS Yearly Current Assets VS Current LiabilitesOCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

OCS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.60%.
EPS 1Y (TTM)-22.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.5%

3.2 Future

OCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.75% yearly.
Based on estimates for the next years, OCS will show a very strong growth in Revenue. The Revenue will grow by 220.00% on average per year.
EPS Next Y5.5%
EPS Next 2Y-1.91%
EPS Next 3Y-4.22%
EPS Next 5Y16.75%
Revenue Next Year-4.46%
Revenue Next 2Y230.48%
Revenue Next 3Y378.69%
Revenue Next 5Y220%

3.3 Evolution

OCS Yearly Revenue VS EstimatesOCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OCS Yearly EPS VS EstimatesOCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCS. In the last year negative earnings were reported.
Also next year OCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCS Price Earnings VS Forward Price EarningsOCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCS Per share dataOCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

OCS's earnings are expected to decrease with -4.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.91%
EPS Next 3Y-4.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCULIS HOLDING AG

NASDAQ:OCS (11/28/2025, 7:52:40 PM)

After market: 19.26 +0.26 (+1.37%)

19

+0.09 (+0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)N/A N/A
Inst Owners31.34%
Inst Owner ChangeN/A
Ins Owners3.04%
Ins Owner ChangeN/A
Market Cap1.10B
Revenue(TTM)N/A
Net Income(TTM)-104.10M
Analysts87.69
Price Target44.73 (135.42%)
Short Float %0.21%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.37%
Min EPS beat(2)-4.51%
Max EPS beat(2)25.25%
EPS beat(4)1
Avg EPS beat(4)-21.81%
Min EPS beat(4)-56.2%
Max EPS beat(4)25.25%
EPS beat(8)3
Avg EPS beat(8)-13.47%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)30.83%
Min Revenue beat(2)24.83%
Max Revenue beat(2)36.82%
Revenue beat(4)3
Avg Revenue beat(4)-2.05%
Min Revenue beat(4)-98.55%
Max Revenue beat(4)36.82%
Revenue beat(8)3
Avg Revenue beat(8)-6.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.61%
PT rev (3m)20.87%
EPS NQ rev (1m)1.98%
EPS NQ rev (3m)8.84%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.22%
Revenue NQ rev (1m)-16.42%
Revenue NQ rev (3m)-13.24%
Revenue NY rev (1m)-4.3%
Revenue NY rev (3m)19.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.14
P/tB 6.83
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-2.71
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.42
OCFYN/A
SpS0
BVpS3.1
TBVpS2.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.02%
ROE -79.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.45%
ROA(5y)-75.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 275.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z 13.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)418.9%
Cap/Depr(5y)255.58%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y5.5%
EPS Next 2Y-1.91%
EPS Next 3Y-4.22%
EPS Next 5Y16.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.5%
Revenue Next Year-4.46%
Revenue Next 2Y230.48%
Revenue Next 3Y378.69%
Revenue Next 5Y220%
EBIT growth 1Y-14.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.09%
EBIT Next 3Y-25.3%
EBIT Next 5Y11.96%
FCF growth 1Y-25.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.63%
OCF growth 3YN/A
OCF growth 5YN/A

OCULIS HOLDING AG / OCS FAQ

Can you provide the ChartMill fundamental rating for OCULIS HOLDING AG?

ChartMill assigns a fundamental rating of 2 / 10 to OCS.


What is the valuation status for OCS stock?

ChartMill assigns a valuation rating of 0 / 10 to OCULIS HOLDING AG (OCS). This can be considered as Overvalued.


Can you provide the profitability details for OCULIS HOLDING AG?

OCULIS HOLDING AG (OCS) has a profitability rating of 0 / 10.


What is the financial health of OCULIS HOLDING AG (OCS) stock?

The financial health rating of OCULIS HOLDING AG (OCS) is 5 / 10.